Podcasts about Mariposa

Paty explains how shame is an internal message of unworthiness while guilt is linked to specific actions. They explore the roots of these feelings, often tied to past experiences, and offer practical strategies for self-regulation to break cycles of intergenerational trauma. Learn how to foster a healthier self-dialogue and pass down positive behavior patterns to your children.04:29 Understanding Trauma-Informed Care07:53 Exploring Mom Guilt and Shame10:46 Differentiating Guilt and Shame18:04 Addressing Core Beliefs, Self-Compassion, and Grieving24:30 Understanding Trauma and Its Impact28:04 Self-Regulation Techniques32:43 Daily Practices for Self-RegulationPaty ‘Mariposa' Hernandez is a Trauma-Informed Licensed Clinical Social Worker and Reiki Master specializing in education, training, and leading retreats. She helps transform stress and trauma into inner peace using complementary therapies. She's happily married with 3 cats in Miami!Connect with Paty ‘Mariposa' Hernandezwww.mariposasholistic.com Connect with Paige BondInstagram: @paigebondcoachingFacebook: @paigebondcoachingTikTok: @paigebondcoachingWebsite: https://paigebond.comPaige Bond is an open relationship coach who specializes in helping individuals, couples, and intentionally non-monogamous relationships with feeling insecure in their relationships. She is also the founder of ⁠Sweet Love Counseling⁠ providing therapy in CO, FL, SC, and VT. Paige loves educating people about relationships through being the host of ⁠the Stubborn Love podcast, ⁠hosting workshops, and speaking at conferences.Free Jealousy Workbook: ⁠⁠⁠http://www.paigebond.com/calm-the-chaos-jealousy-workbook-download⁠⁠⁠ Free People Pleasing Workbook: ⁠⁠⁠https://www.paigebond.com/people-pleasing-workbook⁠⁠⁠ Attachment Dynamics Workshop:⁠https://www.paigebond.com/attachment-dynamics-workshop-sign-up⁠Disclaimer: This podcast and communication through our email are not meant to serve as professional advice or therapy. If you are in need of mental health support, you are encouraged to connect with a licensed mental health professional to receive the support needed.Mental Health Resources: National Suicide Prevention Lifeline: 1-800-273-8255SAMHSA's National Helpline: 1-800-662-HELP (4357)Crisis Text Line: Text HOME to 741741 for free, 24/7 crisis counseling.Intro music by Coma-Media on ⁠⁠pixabay.com⁠

This is part one of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is part two of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Antonio Vega, Efecto Mariposa, Pablo López, Galván Real, Maka, Vicente El Vizio, Bob Marley, Lola Indigo y más artistas . Un viaje diario a través de la buena música, disfruta y goza cada dia con Estación GNG, una dosis diaria de éxitos musicales del ayer y hoy. Que nada nos pare, disfruten con la música. Paz y música

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: •⁠  ⁠The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. •⁠  ⁠Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. •⁠  ⁠Strategies for managing these side effects to improve patient quality of life and treatment adherence. •⁠  ⁠Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!

Gods above have gifted us glory because this week we're discussing season 3, episode 36 of Lucha Underground entitled "The Rise of the Ring Announcer". Come along as we chat about the episode, plus how-do-you-dos, the Batman / Scooby-Doo Mysteries, egging, episode 41 of Mostly Speakin' Sentai entitled, "Did You Say Cucked?", Ric Flair, jeans, Lucha mask culture, wigs, sauciness, non-verbal, Dante Fox praise, yellow lunch boxes, under utilizing Mariposa, crying on stage, Street Fighter 2, the Shaggy doubt, & more!Want to hear more from your favorite Marsh Land Media hosts? Hear exclusive shows, podcasts, and content by heading toPatreon.com/MLMpod!Buy some Shuffling the Deck / MLMpod MERCH, including our "Natty With Otters" shirt, over at redbubble.com/shop/msspod!Follow James @MarshLandMedia on Twitter, @MLMpod on Instagram, and listen to his music under "Marsh Land Monster" wherever music is found! Follow Sean on Twitter @SeanMarciniak and on Twitch @GooseVK! Join ourDiscord!Have fan mail, fan art, projects you want us to review, or whatever you want to send us? You can ship directly to us using "James McCollum, PO Box 180036, 2011 W Montrose Ave, Chicago, IL 60618"! Send us a voice mail to be played on the show at (224) 900-7644!Find out more about James' other podcasts "Mostly Speakin' Sentai", "Hit It & Crit It", and "This Movie's Gay" on our website,www.MLMPod.com!!! Plus, download all Marsh Land Monster albums there, too!

"What kind of saber are you rockin?"Mariposa and Archie bite off more than they can chew during a nighttime canyon crawl.Episode Artwork by @shaunmakesAudio Production by Astronomic AudioMusic by Duke Albert, John Julius, Mike Hammock, and ShubertFeaturing:Shaun as The Game MarshalCristina as Mariposa Dela Cruz RosalesDan as Archie ElseworthJanette as Killdread SprainsShubert as Billy Bigtoes—Need More Bob in Your Life? Check out our other (SFW!) podcast, Tales of BobApple PodcastsSpotify—Support the Show:PatreonMerch StoreContact Us:DiscordTheHouseOfBob.orgTwitterInstagramFacebookEmail—Thank you so much to our current Patreon supporters! This podcast would not be possible without you.MichaelCarlos GShaka JamalEthan EdwardsDan Klip-KlopElliThe Pink PastorGarbanzoD ChanAnette E JordanThomas KuhlmannConnor McCollochPadraig HegartyBrandon KnoxTeam EAMONNPavel LishinChristine BrailleTom InnsElias AndersonMark BoykinJessica ColvinScooter EmersonJosh JordanKeith HaddadTom WesleyJessica

la Mariposa y la Realidad

Mariposa Cruz is the author of Man of the House, the first book in the Knits & Brews series. She joins the Nevada Authors Network to discuss her books and inspirations.Bonus: Mariposa wrote about her experience with CC and JT from Two Moore Books. You can learn more about Mariposa at https://createontheside.wordpress.com/You can learn more about the Sierra Arts Foundation at https://sierraarts.org/You can contact Two Moore Books, LLC via their main website at https://www.carsonhume.com

Comenzamos con este ultrpodcast dedicado al reto igare.cc de Javier García, conocido en redes como Xinolugo. Reto solidario que pretende recaudar fondo para la asociación Debra Piel de Mariposa y la investigación de esta enfermedad rara.Comienza el reto con el Giro 2025 en su particular recorrido por las tres grandes vueltas ciclistas del año, pero no comienza como todos esperábamos, te dejemos que sea Xino quien nos lo cuente en persona.https://igare.ccHaz tu donación al reto -> https://www.migranodearena.org/reto/igareBSO: https://calmaquebranto.bandcamp.com/album/otras-formas-de-arderEmpresas colaboradoras con el reto:@pieldemariposa @ritcheylogic@frasen_wheelworks@geosminacomponents@mountain_group@lezyneofficial@oldmanmountainracks@fmchallenge@silca_velo@ruta_29 @novafis_fisioterapia@selo_roupabonita@strava@reneherse

In March 2021, workers at the Mariposa Food Co-Op in West Philly formed a union with UFCW Local 1776. Today, they're working to build more power in order to make Mariposa into an even better place to work. Originally aired: February 13, 2023.Support the showwww.laborjawn.com

Conafor reporta 77 incendios activos en 17 estadosImpugnarán a "una veintena" de candidatos al Poder JudicialIsrael prometió represalias contra el régimen de IránMás información en nuestro Podcast

Una oruga que sueña con ser la mariposa mensajera de la primavera comienza su viaje con fe y valentía.Mi Instagram:⁠⁠https://instagram.com/cuentos_e_historias_infantiles⁠⁠Mi Facebook:⁠⁠https://www.facebook.com/CuentosHistoriasMexico⁠

The Mariposa Center for Safety, based out of Pueblo, does wonderful things to help people who are victims of domestic violence. Hear about the awesome event they've got coming up for Mother's Day and how you can help!Follow us for even more fun local radio content!https://www.facebook.com/x1039radio https://www.instagram.com/x1039radio

Recorded by Mariposa Fernández for Poem-a-Day, a series produced by the Academy of American Poets. Published on April 29, 2025. www.poets.org

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en longarts Joop de Langen, werkzaam in het Antoni van Leeuwenhoek te Amsterdam, over de laatste ontwikkelingen met betrekking tot de behandeling van longkanker gepresenteerd tijdens The European Lung Cancer Congress 2025. Aan bod komen onder andere de MARIPOSA-, SAVANNAH-, de ADRIATIC- en de 3475A-D77-studie en ontwikkelingen met betrekking tot KRAS-remmers.

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025. We dived into several key studies that are shaping the future of lung cancer treatment, including: • KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC). • LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy. • MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC. • KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy. Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies. YouTube: https://youtu.be/akoXXAUEl_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast

Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.Join Us

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

WWF-México y la Comisión Nacional de Áreas Naturales Protegidas de México, en colaboración con las comunidades locales, realizaron un informe sobre la población de mariposas monarca migratorias en el país. Eduardo Rendón Salinas, director de Ecosistemas Terrestres WWF México, habló en Aristegui sobre las principales amenazas que enfrentan estas mariposas en el continente y puntualizó los logros alcanzados en la conservación de esta especie. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Apúntate para unirte al Club Agibílibus: ⁠⁠⁠https://borjaprofe.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠También recibirás un regalo CANÍBAL y más contenidos chulos cada semana.Gracias a Laura por venirse al podcast :) Puedes conocerla mejor en:⁠IG: @soy.lauraserranoNewsletter: https://subscribepage.io/W31LY5

In this intimate and candid episode, we sit down with Mariposa Coalson (@suchagreatsky), a transgender artist and comedian making waves in New York City's creative scene. Joined by her roommate Gabriel Gara Lonning, Mariposa takes on thought-provoking questions from the MTF Reddit community, offering honest insights and personal experiences. The conversation takes unexpected turns as Gabriel shares his own journey of exploring identity, including the surprising challenges of shopping for a changing body, and offers a critical perspective on conformity within the trans community. Raw, funny, and refreshingly honest, this episode dives deep into the realities of gender, identity, and finding authenticity in the big city.https://www.patreon.com/c/garalonningSupport the show

Tercer Milenio 360 Internacional - 10/03/25Fin de semana de terror en Siria. Al menos mil muertos en choques entre fuerzas leales al ex presidente Bashar Al Assad y fuerzas de seguridad oficiales. La liga Árabe condena la violencia.Se duplica la superficie de bosque ocupada por la mariposa monarca en México debido a las mejores condiciones climatológicas.La tarde del 3 de marzo del 2025, residentes de Miami, Florida, captan lo que parece ser un portal dimensional o magnético.Sao Paulo,  Brasil, se ha convertido en zona de intensa actividad OVNI. La noche del 3 de marzo, un residente registra con su teléfono celular un objeto brillante con base cuadrangular que se desplazaba lentamente y en linealidad recta.  

Primer transplante de corazón este 2025 se realizó en el IMSS Aumentó al 99% la presencia de la mariposa monarca en México  EU debe enfrentar el problema del fentanilo:China  Más información en nuestro podcast 

En nuestro episodio 434 conversamos con Gabriel Meneses Global CHRO en Grupo Mariposa, antes fue el Global VP de Talento en Netflix sobre:+ El desafío de llevar talento mexicano a liderar en Estados Unidos.+ Cómo el futuro del trabajo está siendo moldeado por nuevos modelos de trabajo.+ El significado de gestionar talento en empresas globales.+ El éxito no es tener las credenciales correctas, sino de entender el contexto en el que operas.+ La resiliencia no es solo aguantar, es evolucionar. + Tener una gran ética de trabajo. + El liderazgo no es control, es empoderar.Únete a la cohorte #7 de la Academia Hackers del Talento Latam aquí: https://www.hackersdeltalento.com/academia-hackers-del-talento

We're joined by Bridget Fithian, Executive Director of the Sierra Foothill Conservancy and a leader in land conservation across the Central Sierra. Born and raised in Mariposa, Bridget's deep connection to open spaces has shaped her career in conservation, where she has helped protect over 30,000 acres of land through innovative partnerships and creative solutions.  Under her leadership, the Sierra Foothill Conservancy has expanded public access to nature, preserved critical landscapes, and played a key role in conservation planning, fire resilience, and environmental stewardship. Bridget also serves as Board Chair of the California Council of Land Trusts and holds leadership roles with the Sierra Cascade Land Trust Council and the California Conservation Action Fund.  In this episode, we'll explore how land trusts shape conservation, the role of environmental planning, and what it takes to protect and restore California's landscapes for future generations.  

Miguel del Pino nos advierte de esa pequeña y peligrosa oruga que llena los pinares españoles, ¡en directo!

Aprovecha la promoción exclusiva de NordVPN y Leyendas Legendarias y obtén 4 meses gratis: https://nordvpn.com/legendarias Notas Macabrosas - Muere un joven de 14 años por inyectarse 'jugo de mariposa' - Una prueba de ADN confirma que las lágrimas de la Virgen de Trevignano eran de una vidente - Presunto artefacto explosivo resulta ser un envase de perfume - Escapando de la “granja de huevos humanos”: tres mujeres escapan de una impactante red de tráfico de personas - Mujer se divorcia porque su esposo abucheó a Taylor Swift en Super Bowl - Atleta de 17 años murió mientras levantaba una barra con 270 kg  - 157 delfines fueron hallados varados en una playa de Tasmania  - California avanza hacia el reconocimiento oficial de Bigfoot  - Rescatan a hombre encerrado en baño de Elektra  - Hombre es detenido en aeropuerto con 19 cápsulas de cocaína en una peluca  - Un hombre mata a su esposa después de que un medidor paranormal le provocara temores de que ella se lo comería Redditeando - Lolo nos trae un hilo de reddit con respuestas a la pregunta: ¿Cuál es tu “rasgo de asesino en serie” que (hipotéticamente) haría que todos dijeran: “Deberíamos haberlo sabido”? También puedes escucharnos en Youtube, Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast​ Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Síguenos: https://instagram.com/leyendaspodcast​ https://twitter.com/leyendaspodcast​ https://facebook.com/leyendaspodcast​ #Podcast​ #LeyendasLegendarias​ #HistoriasDelMasAca Learn more about your ad choices. Visit megaphone.fm/adchoices

Aprovecha la promoción exclusiva de NordVPN y Leyendas Legendarias y obtén 4 meses gratis: https://nordvpn.com/legendarias Notas Macabrosas - Muere un joven de 14 años por inyectarse 'jugo de mariposa' - Una prueba de ADN confirma que las lágrimas de la Virgen de Trevignano eran de una vidente - Presunto artefacto explosivo resulta ser un envase de perfume - Escapando de la “granja de huevos humanos”: tres mujeres escapan de una impactante red de tráfico de personas - Mujer se divorcia porque su esposo abucheó a Taylor Swift en Super Bowl - Atleta de 17 años murió mientras levantaba una barra con 270 kg  - 157 delfines fueron hallados varados en una playa de Tasmania  - California avanza hacia el reconocimiento oficial de Bigfoot  - Rescatan a hombre encerrado en baño de Elektra  - Hombre es detenido en aeropuerto con 19 cápsulas de cocaína en una peluca  - Un hombre mata a su esposa después de que un medidor paranormal le provocara temores de que ella se lo comería Redditeando - Lolo nos trae un hilo de reddit con respuestas a la pregunta: ¿Cuál es tu “rasgo de asesino en serie” que (hipotéticamente) haría que todos dijeran: “Deberíamos haberlo sabido”? También puedes escucharnos en Youtube, Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast​ Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Síguenos: https://instagram.com/leyendaspodcast​ https://twitter.com/leyendaspodcast​ https://facebook.com/leyendaspodcast​ #Podcast​ #LeyendasLegendarias​ #HistoriasDelMasAca Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Jyoti Patel is back on the podcast to discuss the updates to the living guideline on therapy for stage IV NSCLC with driver alterations. She shares updated recommendations in the first- and second-line settings for patients with stage IV NSCLC and classical EGFR mutations, and the impact of these updates for clinicians and patients. We also look to the future to discuss ongoing developments in the field. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02785     Brittany Harvey: Welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jyoti Patel from Northwestern University, co-chair on “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.” It's great to have you back on the show today, Dr. Patel. Dr. Jyoti Patel: Thanks so much. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel, who has joined us here today, are available online with the publication of the guideline and in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content of this update, Dr. Patel, this clinical practice guideline for systemic therapy for patients with stage IV non small cell lung cancer with driver alterations is living, meaning that it's continuously reviewed and updated. So what data prompted this latest change to the recommendations? Dr. Jyoti Patel: Thanks so much. So it's really been an exciting time in the treatment of EGFR lung cancer, particularly this past year has required us to rethink approaches to front- and second-line therapy. In this particular update, we examined what patients in the front-line setting may be offered by their clinicians. And so we're talking about the population of classical EGFR mutations, so exon 19 and exon 21 L858R substitution. And so certainly for this population, osimertinib has a high level of evidence and should be offered to all patients at the time of diagnosis when they present with advanced disease. Our last update included a recommendation that patients could also get platinum doublet chemotherapy with osimertinib or osimertinib alone. This current recommendation also introduces another alternative therapy and that's the combination of amivantamab plus lazertinib. And so now, clinicians are faced with three really good options for their patients with EGFR exon19 deletion or L858R. Brittany Harvey: It's great to hear that there's this advance in the space, particularly for patients with these classical EGFR mutations that you mentioned. So what should clinicians know as they implement these new first-line recommendations? Dr. Jyoti Patel:  I think it's become more complex than ever. Certainly, we know again that patients should get osimertinib in the frontline setting. But we've been kind of stuck at progression-free survival that's between a year and a half and two years. And so we've really been looking at opportunities to intensify therapy. So one could certainly be with chemotherapy or switching over to amivantamab, the bispecific antibody that targets EGFR and MET plus lazertinib, an oral TKI that's very similar in structure to osimertinib. And when you're talking to a patient, it's really a conversation about balancing efficacy with toxicity. Unfortunately, as we know, there aren't that many free lunches. And so if we think about what a patient is hoping for in their therapy and how we can further personalize treatment options, really is important to look at some of the analyses for this study. So in the study of amivantamab plus lazertinib, we know that there were increased toxicities with a combination of both therapies. In fact, up to 75% of patients had over grade 3 toxicities, versus about 43% of patients with osimertinib monotherapy. And we know if we look back at FLAURA2, almost two thirds of patients with osimertinib and chemotherapy had grade 3 toxicities, compared to 27% of patients with osimertinib alone. So we certainly see an increase in toxicities. Then we have to ask ourselves, are those paper toxicities or ones that really impact patients? And we know that amivantamab, for example, causes significant cutaneous toxicities. With both of these therapies, whether it's chemotherapy or adding amivantamab, there's the burden of infusional visits and increased time in the doctor's office. Certainly with chemotherapy, there can be an increased incidence of myelosuppression. And so when we're thinking about advising our patients, certainly we need to talk about the toxicities. But one thing that we've been able to do is to look at the patients that were included in this trial. And what we really find is that in higher risk cohorts, particularly those that we know historically have done less well with standard osimertinib, so patients, for example, with CNS metastasis, for those patients with co-mutations, it may be that that additive benefit is significant. And so one example I think would be from the MARIPOSA study, again, the study of amivantamab and lazertinib versus chemotherapy. What we can say is that patients who had co-mutations, so patients with EGFR mutations as well as TP53, lazertinib and amivantamab led to a hazard ratio of 0.65 compared to osimertinib alone. So that was 18.2 months versus 12.9 months. And so this may be really important to patients. And we also see conversely that patients with wild type TP53, so those patients who didn't have the mutation, probably had equivalent survival regardless of therapy. So certainly, we need to prospectively study some of these high-risk cohorts. We've only seen progression-free survival in these studies. And so at this juncture, we can advise our patients about toxicity, the improvements in certain categories of progression-free survival, but we really still don't know how this pans out in overall survival. In many of these studies, all patients do not necessarily cross over to the study arm and so they may have lost the benefit of subsequent therapy. Brittany Harvey: Absolutely. It's very important to talk about that balance of benefits and risks and particularly those toxicities that you discussed. So I appreciate reviewing that recommendation and the considerations for clinicians for first-line therapy. This update also included a second-line treatment update. What is that update for patients with EGFR alterations? Dr. Jyoti Patel: So this is where it gets super tricky because we have a frontline option with amivantamab and now we've had an update in the second line option. So what we said is that for patients who have progressed on an EGFR TKI, and in the United States, certainly that's predominantly osimertinib, or those in other parts of the world that may have gotten an earlier generation TKI, but do not have evidence of T790M or other targetable mutations, we can offer patients chemotherapy with or without amivantamab. And so certainly we have seen that this again leads to improved survival. There have also been a number of studies looking at incorporation of PD-L1 and anti-VEGF therapies. And what we can say, I think pretty clearly is that multiple phase 3 trials have really shown no benefit of the addition of PD-1 to platinum chemotherapy. But there are some emerging bispecific antibodies that may target PD-1 as well as VEGF, or combinations of antibodies that target both of those pathways that may improve outcome. At this juncture, I think we feel that the evidence surrounding chemotherapy plus amivantamab is strongest, but there is certainly work in this space that will be of interest. Now, what happens if your patient received amivantamab and lazertinib in the frontline setting and then has progression? And so we're trying to understand resistance mechanisms and opportunities for treatment. What the panel decided to recommend, based on the available evidence, was that certainly those patients should get platinum-based chemotherapy, but there may also be a role for antivascular endothelial growth factor targeting therapy such as bevacizumab in patients in whom it would be safe. Brittany Harvey: Great. I appreciate you detailing those recommendations when it gets complicated in the second-line setting. So what should clinicians know as they implement these second-line recommendations too? Dr. Jyoti Patel: So certainly the frontline setting matters significantly. So if a patient gets osimertinib in the frontline setting, we generally suggest that patients undergo repeat testing to see if they have another targetable mutation. If they don't, then I think preferred therapy would be chemotherapy with or without amivantamab. And amivantamab leads to a significant improvement in progression-free survival and response rate at the cost of increased risk of toxicity. For patients who get FLAURA2 in the frontline setting, chemotherapy plus osimertinib, it's a little bit of an unclear space. Those patients most likely would get docetaxel with or without ramucirumab. But there are other agents that we hope to have available to our patients in the near future. For patients who receive amivantamab and osimertinib, we recommend that those patients get chemotherapy probably with anti-VEGF as demonstrated by multiple trials that have shown the improved progression-free survival with introduction of an anti-VEGF agent. And we've seen evidence of amivantamab in the third line setting, so it is likely that this question about sequencing really takes center stage in our next set of trials. When you're talking to a patient, I think again, it's absolutely important to discuss: What are their goals? How symptomatic or how fast is their progression? Are there ways in which patients may benefit from spot treatment oligoprogression such as radiation? When is the right time for introduction of amivantamab and when do we think patients need chemotherapy? Is it up front or predominantly in the second-line setting? Brittany Harvey: Definitely. And then you've just touched on the goals of treatment for individual patients. So in your view, what does this update mean for patients with stage IV non-small cell lung cancer and an EGFR alteration? Dr. Jyoti Patel: For patients, this is a time in which shared decision making really needs to take center stage. So our best patients are those patients that are best informed not only about their disease but also have a good understanding about what is important to them and their families in terms of care. And so bringing that shared understanding to the table again helps us think about this particular cancer as more of a journey rather than just a one off treatment. Therapy will hopefully be prolonged, and so it's absolutely important that we address toxicities, make therapies more tolerable, again, with the shared goal of living long and living well. Brittany Harvey: Absolutely. Those are key points to making sure that patients are living both longer and have a good quality of life during that time as well. So then, before you mentioned the possibility of future sequencing trials and other ongoing developments. What additional studies or future directions is the panel examining for future updates to this living guideline? Dr. Jyoti Patel: So certainly we're thinking about trials that look at, for example, cfDNA clearance. So are there patients that do well and can we detect that early on without having to intensify therapy on day 1 so it may be that we add chemotherapy a little bit later. I think really exciting are some of the new bispecific. The HARMONi-A trial was a trial in China of a novel bispecific, ivonescimab. And this drug targets both PD-1 and VEGF and it was combined with chemotherapy. And this trial found almost a doubling of progression-free survival with this drug in combination chemotherapy in an EGFR patient population. That study is being planned and being run in the United States to see if we have similar outcomes with a more diverse population. So certainly that's exciting. There are a number of antibody drug conjugates that are being studied in the post-chemotherapy setting as well. And I think we'll likely soon see a better understanding of what co-mutations and burden of disease really mean when we're thinking about assigning treatment. So which patients, again, need intensification of therapy and which patients may do really well on just an oral agent that they're taking at home with more tolerable toxicity than dual treatment. Brittany Harvey: Yes, we'll look forward to continued developments in these fields and seeing some of those studies come to fruition. So with that, I want to thank you for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Patel. Dr. Jyoti Patel: Thanks so much, Brittany. It's really an exciting time for lung cancer and we hope that these updates really help physicians decide the best treatments for their patients. Again, it's a rapidly evolving landscape which is fantastic, but it does become more cumbersome to stay ahead of the literature. Brittany Harvey: Definitely. And so we appreciate your time and the panel's time spent reviewing this literature and providing this much needed information to clinicians everywhere. So finally, thank you to all of our listeners for tuning into the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the  Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Biochemical and forensic experts from the Science and Technology Directorate (S&T) and Pacific Northwest National Laboratory (PNNL) visited one of the nation's busiest (and loudest) ports of entry in Mariposa, Arizona. With this as our backdrop, listen as the group discusses research and development of a novel fentanyl detector designed to improve screening for illicit drugs. S&T's Dan Conway leads a conversation with Dr. Andrea Wiggins of S&T's Chemical Biological Detection and Defense Program; Travis Brown, S&T Program Manager for Forensics and Criminal Investigation; Dr. Laura Parker, S&T Senior Advisor on Sensors and Detection; and PNNL Senior Research Chemist Dr. Robert Ewing about how this new technology was demonstrated and could soon be used and overall challenges with combating the flow of fentanyl.

We meet legendary artist Peter Berlin from his home in San Francisco. Peter Berlin (born Armin Hagen Freiherr von Hoyningen-Huene) is a photographer, artist, filmmaker, clothing designer, model, and gay icon. Berlin started taking self-portraits of himself in the 1970s. By modifying his clothes, choosing various props and settings, and sometimes using double-exposure to create a second image, Berlin would photograph himself in ways that create a hyper-sexualized, overtly masculine image.We explore Mariposa Gallery's inaugural Los Angeles exhibition featuring the groundbreaking photography, art, and personal artifacts of Peter Berlin, an artist who transformed queer self-representation and male eroticism in the 1970s and beyond. The exhibition set to open at 526 N. Western Avenue—in the heart of the Melrose Hill gallery district— is curated by actor and host of Talk Art, Russell Tovey, and will showcase Berlin's iconic self-portraits, unique painted photographs, and items from his personal archive including his own clothing designed by Berlin during his years as a self-styled gay icon. This is the first ever exhibition of Berlin's work in Los Angeles.The exhibition offers visitors a rare view into the life and work of an artist whose influence on LGBTQ+ aesthetics endures. Berlin, born Armin Hagen Freiherr von Hoyningen Huene in 1942, gained notoriety for his daring and meticulously crafted self-portraits, often taken in public spaces across Berlin, Paris, New York, and San Francisco. These images capture Berlin in his skin-tight costumes and signature pageboy haircut, boldly challenging the boundaries of masculinity and public identity.Berlin's focus on “cruising as career” drew him to create self-portraits that explored male sexuality and queer expression, which appeared on the covers of numerous gay publications, cementing his image as an international gay sex symbol. The exhibition will also feature selections from Berlin's '70s and '80s media presence, capturing the evolution of gay aesthetics in this era."Peter Berlin, the fearless and enigmatic, otherworldly icon of 1970s cruise culture, created work that resonates around the world—sparkling, searing, and blazing with vitality. His images burn with eternal desire, offering us the ultimate permission to stare. It's a privilege to share his groundbreaking art with new and familiar audiences alike. Peter Berlin remains a profoundly significant yet often overlooked figure in the history of art." - Russell ToveyBerlin's influence extended to film, including Nights in Black Leather (1973) and That Boy (1974), both now cult classics. A recent 2019 monograph on his work, Icon, Artist, Photosexual, highlights his impact, featuring insights from Michael Bullock, Evan Moffitt, and Ted Stansfield, each celebrating Berlin's singular contribution to queer art and culture. Mariposa Gallery invites the public to step into Berlin's world and experience the legacy of an artist who, through bold self-exploration and defiant artistry, redefined eroticism and individuality in the queer community.Materials on loan from the Peter Berlin Collection courtesy of Armin Hagen von Hoyningen-Huene and with guidance from Gerard Koskovich, the historian and dealer offering the collection for institutional acquisition. For more information, visit www.abaa.org/booksellers/details/gerard-koskovich-queer-antiquarian-books.Follow @PeterBerlinSF and @Mariposa.DriveVisit: https://www.mariposa.gallery/berlin Hosted on Acast. See acast.com/privacy for more information.

Excellence abounds at 1850 Brewing in Mariposa, California. And then Bob had to bring in some other mess just so we could all appreciate the excellence.

Screw cousins, these wrestlers are snoggin' siblings because this week we're discussing season 3, episode 23 of Lucha Underground entitled "Family First". Come along as we chat about the episode, plus sphincters, a new Fenix, Hellboy, MST3k, "Big Momma's House 2", thighs / heads, "The Grease", urine, "Gauntlet Legends", Snopes, pewb mounds, "Scary Movie 2", esophagus pronunciations, DX Chops, DQing wrestlers not in the ring, live commentary, dropkicks, mist, & more!Want to hear more from your favorite Marsh Land Media hosts? Hear exclusive shows, podcasts, and content by heading toPatreon.com/MLMpod!Buy some Shuffling the Deck / MLMpod MERCH, including our "Natty With Otters" shirt, over atredbubble.com/shop/msspod!Follow James @MarshLandMedia on Twitter, @MLMpod on Instagram, and listen to his music under "Marsh Land Monster" wherever music is found! Follow Sean on Twitter @SeanMarciniak and on Twitch @GooseVK! Join ourDiscord!Have fan mail, fan art, projects you want us to review, or whatever you want to send us? You can ship directly to us using "James McCollum, PO Box 180036, 2011 W Montrose Ave, Chicago, IL 60618"! Send us a voice mail to be played on the show at (224) 900-7644!Find out more about James' other podcasts "Mostly Speakin' Sentai", "Hit It & Crit It", and "This Movie's Gay" on our website,www.MLMPod.com!!! Plus, download all Marsh Land Monster albums there, too!

In the first edition of a special 3-part podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about best practices for implementing recently approved bispecific antibodies into cancer care. Their initial discussion focused on the clinical trial results, administration protocols, and toxicity management strategies related to the use of amivantamab-vmjw (Rybrevant) for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Morgensztern is a professor of Medicine and clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University in St. Louis. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine in St. Louis and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. Morgensztern began by giving an overview of amivantamab's mechanism of action and highlighting supporting data for the agent when administered alone or in combination with other agents.  The FDA initially approved amivantamab monotherapy for patients with EGFR exon 20 insertion–mutant NSCLC in May 2021 based on data from the phase 1 CHRYSALIS trial (NCT02609776). Furthermore, the agency approved amivantamab/chemotherapy as frontline treatment for patients with NSCLC harboring EGFR exon 20 insertion mutations in March 2024 based on data from the phase 3 PAPILLON trial (NCT04538664). Findings from the phase 3 MARIPOSA trial (NCT04487080) also supported the FDA approval of amivantamab plus lazertinib (Lazcluze) for those with EGFR-mutant NSCLC in August 2024. Additionally, Mann reviewed key dosing considerations as patients receive amivantamab via intravenous infusion. She detailed the use of premedication such as diphenhydramine (Benadryl) to supplement amivantamab while monitoring for toxicities during the initial infusion period, which may necessitate additional dosing adjustments. Flanagan added to the conversation surrounding infusion-related reactions by describing strategies for mitigating the risk of venous thromboembolism, cutaneous toxicities, and other adverse effects. References 1. RYBREVANTTM (amivantamab-vmjw) receives FDA approval as the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. News release. The Janssen Pharmaceutical Companies of Johnson & Johnson. May 21, 2021. Accessed January 29, 2025. https://tinyurl.com/3d8wtu4m 2. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. News release. FDA. March 1, 2024. Accessed January 29, 2025. https://tinyurl.com/msw4u5yk 3. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. News release. Johnson & Johnson. August 20, 2024. Accessed January 29, 2025. https://tinyurl.com/yxc8u8t4

Científicos registran uno de los vuelos más largos que ha hecho una mariposa: 3,000 kilómetros de distancia. Esucha esta y otras noticias positivas.

¡Sean ustedes bienvenidas al episodio 93 de esta temporada! El día de hoy hablaremos de la obra: “Los Miserables” de Victor Hugo. ¿Qué nos enseña esta historia sobre la ley y la misericordia? Esta historia ha sido llevada a teatros en Broadway y a la pantalla grande en varias ocasiones. ¡Muchas gracias por ser parte de esta comunidad! No lo olvides. ¡Estamos juntas en esto! Todos los derechos reservados. Copyright 2025 © Estíbaliz Delgado Amaya

El Sueño de la Mariposa

Gracias a Alessa Niño Capira desde Australia que nos ha dejado esta historia muy tierna sobre una mariposita llena de temores. Afortunadamente conoce a una persona muy especial que lo cambiará todo.Sígueme en Instagram @tiabotas, Facebook @latiabotas y en mi canal en Youtube Tía Botas Oficial. Adquiere mis libros digitales en cualquier App de ebooks, como Amazon Kindle, Apple Books o Google Play books, búscame como Tía Botas o como Magda Botteri. Y escucha todas mis canciones en Spotify. Visita mi web: latiabotas.comYa puedes compras mis libros físicos de Los amigos del mar en buscalibre.com de tu país. Búscalos por el nombre del cuento.

A new Gift of the Gods Champion is crowned; Mariposa motivates her broken-armed brother Marty "The Moth" Martinez; Sammy Guevara looks for revenge against " The Savage" Jake Strong.

Mariposa makes a proposal to Antonio Cueto; Paul London makes an offering to the Gods on behalf of the White Rabbit; The Worldwide Underground take on The Reptile Tribe in an Atomicos Match...If The Reptiles win, Johnny Mundo must join them.

In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was rejoined by Stephen Liu, MD, a thoracic oncologist and the Head of Developmental Therapeutics at Georgetown University's Lombardi Comprehensive Cancer Center in Washington, DC.  Their conversation encompassed findings from the phase 3 MARIPOSA trial (NCT04487080) investigating amivantamab-vmjw (Rybrevant) plus lazertinib (lacluze) in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC); toxicities associated with amivantamab and lazertinib to be aware of; the potential future implications of findings from the phase 3 PALOMA-3 trial (NCT05388669) of lazertinib plus subcutaneous amivantamab in patients with EGFR-mutated advanced or metastatic NSCLC; and how all these agents may fit into the NSCLC treatment armamentarium going forward.

Derrama económica de 20 mmdp por festividades en honor a la Virgen de GuadalupeNo se logra acuerdo para terna a cubrir la vacante del titular de la FGJ de la CDMX Evacuan a habitantes en NL por un fuerte incendioMás información en nuestro Podcast

CORREOS CON LOS QUE SE DIO LENGUA: 

Cerran al público, reserva de la Mariposa Monarca en el ejido de San JuanDetienen a dos integrantes de los Beltrán LeyvaCharles Kushner será el nuevo embajador de EU en FranciaMás información en nuestro Podcast

Maggie "Mariposa" Konopasek and Kyle "Bits" Ott sit down in the Hiker Trash Radio studio to talk about the grand finale to their 2024 thru hike of the PCT. Settle in and buckle up as these two completionists fill Doc in on the hijinks and adventures through the state of Washington, including rodents in the tent, desperation in the rain, public use cabins, recovering trail miles in California, sweaty bus rides, Johnny Appleseed, knives duct-taped to hiking polls, relationship goals, Mt. Rainier views, and future plans. Epic. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Lyudmila Bazheova share the latest updates to the ASCO living guideline on therapy for stage IV non-small cell lung cancer with driver alterations. She discusses changes for patients with EGFR driver alterations in both the first- and second-line setting, and reviews the evidence supporting these updated recommendations, from trials such as MARIPOSA, MARIPOSA-2, CheckMate 722, and KEYNOTE-789. Stay tuned for future updates to this continuously updated guideline. Read the full update, “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02133   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, lead author on “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.” Thank you for being here, Dr. Bazhenova. Dr. Lyudmila Bazhenova: It is my pleasure. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us on this episode today, are available online with the publication of the guideline update in the Journal of Clinical Oncology, which is linked in the show notes. So then, to kick us off on the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is being updated routinely as a living guideline. So what prompted the update to the recommendations in this latest version? Dr. Lyudmila Bazhenova: Living ASCO Guidelines are developed to keep up with rapidly changing evidence which affect treatment of our patients with lung cancer. In this recently published guideline, we reviewed new evidence for patients with metastatic lung cancer harboring driver alterations. We reviewed evidence from four published studies, MARIPOSA, MARIPOSA-2, CheckMate 722 and KEYNOTE-789 that resulted in updated guidelines. Brittany Harvey: Great. And then based off those four trials that you just mentioned, what are the updated recommendations for patients with stage IV non-small cell lung cancer and an EGFR exon 19 deletion or exon 21 L858R substitution? Dr. Lyudmila Bazhenova: In the previous guideline, we detailed FLAURA 2 study which was presented and published in the past. In this guideline, we specifically highlighted a phase 3 MARIPOSA trial which took patients with untreated advanced non-small cell lung cancer which harbored classical EGFR mutations such as EGFR deletion 19 and L858R. In this study, patients were randomly assigned to receive amivantamab plus lazertinib or osimertinib or lazertinib alone. And the study showed that the primary endpoint which was progression-free survival was longer with amivantamab plus lazertinib compared to osimertinib, and numerically the progression free survival was 23.7 months with ami-lazertinib versus 16.6 months with osimertinib which was statistically significant. The challenge that we have to face when discussing that option with our patients is increased toxicity with amivantamab and lazertinib combination. For example grade 3 treatment adverse events were 75% with amivantamab and lazertinib and 43% with osimertinib. So this will require shared decision making between our patients and ourselves. We also noticed in the guidelines that there was a subgroup analysis of that study showing that the patients with a higher disease burden, central nervous metastasis or brain metastasis as well as disease which considered to be a higher risk such as commutation, for example, p53 and liver metastasis, they might benefit from intensified therapy. However, another thing that we are highlighting in the guideline is that at this point we do not know how the intensification of therapy will change overall survival of our patients. So one needs to take into account increased toxicity with that combination. Brittany Harvey: So then Dr. Bazhenova, in addition to those updates for first line therapy, what are the updated recommendations for second line therapy? Dr. Lyudmila Bazhenova: For patients who have progressive disease on osimertinib or other EGFR tyrosine kinase inhibitors, we also updated our guidelines highlighting MARIPOSA 2 study. In the MARIPOSA 2 study, patients were assigned to chemotherapy versus amivantamab plus lazertinib plus chemotherapy versus amivantamab plus chemotherapy. And both of the amivantamab arms showed superiority in progression-free survival compared to chemotherapy alone arm and therefore this becomes an additional treatment option for our patients who develop resistance to osimertinib. In addition, we also updated the results which highlight the lack of efficacy of immunotherapy in the patients who progressed on osimertinib. There were two studies that we highlighted. One of them was a CheckMate 722 which randomly assigned patients with metastatic non-small cell lung cancer whose cancer has progressed on EGFR tyrosine kinase inhibitor to receive either chemotherapy or chemotherapy plus nivolumab which is an immune checkpoint inhibitor. And the second study was KEYNOTE-789 which had a very similar study design. Again, patients who progressed on EGFR TKI also were assigned to receive chemotherapy plus pembrolizumab or chemotherapy alone and in both of those studies there was no improvement in progression-free survival when adding immunotherapy to chemotherapy. So for all your patients who are progressing on EGFR tyrosine kinase inhibitors and you're thinking if additional immunotherapy is necessary, we now have two randomized phase 3 studies telling us that immunotherapy should not be used in addition to chemotherapy for patients who develop progression on osimertinib. Brittany Harvey: Understood. I appreciate you talking about the evidence that supports these latest recommendations from the expert panel. So then you've already touched on this a little bit in mentioning shared decision making and discussing toxicity with these new therapies, but what should clinicians know as they implement these new recommendations and how do these new recommendations fit into the previous recommendations made by the panel? Dr. Lyudmila Bazhenova: Our previous recommendations did not include a MARIPOSA trial, so did not include amivantamab and lazertinib. So in our current guidelines for patients with newly diagnosed treatment-naive EGFR classical mutations, we have three options. Number one is osimertinib, number two is osimertinib plus chemotherapy based on the FLAURA study that we highlighted in the prior version of the guidelines. And the third is amivantamab plus lazertinib. At this point, we do not have any randomized head-to-head studies of those combinations with an exception of FLAURA 2 which is osimertinib plus chemo versus osimertinib. And so the decisions will have to be made on a cross-trial comparison, taking into account patient wishes if they would like to receive chemotherapy or amivantamab plus lazertinib, understanding that this combination will result in increased toxicity. Brittany Harvey: Absolutely. I appreciate you detailing those considerations. So then finally, what do these new options mean for patients with non-small cell lung cancer and an EGFR alteration? Dr. Lyudmila Bazhenova: As a patient, it is important to also be aware of what options we have and have a direct dialogue with the physician, with the treating physician, trying to understand what option will fit with each individual patient's goals, life goals, as well as toxicity concerns. Brittany Harvey: Definitely. It's always great to have more options for patients and it's also important to discuss all of those options with their clinician as well. So I want to thank you so much for your work on this update and thank you for your time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Climbing the 3,000-foot vertical rock El Capitan may sound like an extreme sport to most people, but for Ken Yager, it's a way to relax and be centered. “I get a focus up there like I've never had before,” said Yager, who had his first attempt at the age of 13, and eventually succeeded in 1977, when he was 18 years old. For decades after, he kept climbing and coaching the younger generation. Meanwhile, he established a climbing museum in Mariposa and an exhibit in Yosemite, as well as initiated and led a famous cleaning effort in Yosemite National Park. “What I really like about it is that this energy that builds up as it goes, everybody's feeling really good about cleaning the park. ... It's one of the few times now—there's a lot of animosity and a lot of kind of a split country right now, but this event seems to bring everybody together,” Yager said. Today, Yager will talk about his climbing career and some of the most unforgettable experiences he had while hanging on the cliff, as well as his effort in promoting the sport and preserving its history. ⭕️ Watch in-depth videos based on Truth & Tradition at Epoch TV

FDA has been busy the last week approving: -ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement -osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC -amivantamab + chemotherapy following progression on osimertinib (Mariposa-2) -a subcutaneous formulation of atezolizumab -isatuximab + VRD for multiple myeloma -pembrolizumab + chemotherapy for metastatic pleural mesothelioma